BUSINESSSTAT NEWS
STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals for $10 billion, gaining access to Palsonify, a drug for acromegaly, and other drug candidates. The deal marks Vertex's largest acquisition as it expands beyond its cystic fibrosis portfolio.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
- AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B